Augmentation Therapy

Alpha-1 therapy involves the intravenous infusion of purified, human-derived A1AT.7

The goal of therapy is to raise the A1AT levels above the protective threshold of 11 μM (57.2 mg/dL).7

Other treatment options may include:

  • Symptomatic treatment with inhalers
  • Pulmonary rehabilitation
  • Surgery (in some cases)
checkmark icon
In clinical trials, ZEMAIRA has been proven to raise and maintain levels of A1AT for chronic augmentation and maintenance therapy.20

Clinical data demonstrating the long-term effects of chronic augmentation therapy are not available.

Start ZEMAIRA for your Alpha-1 patient

Contact a ZEMAIRA sales representative today

CALL 1-855-ZEMAIRA (1-855-936-2472) or EMAIL Zemairasupport@CSLBehringsales.com

You are now leaving the current website.